BDX · Categories · Leadership
BDX - Leadership updates
Becton Dickinson and Company (BDX) leadership updates - real-time wire coverage filtered to Leadership only.
Recent Leadership for BDX
- BD Appoints Vitor Roque Chief Financial OfficerFRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio
- Waters Completes Combination with BD's Biosciences & Diagnostic Solutions BusinessesAnnounces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies
- BD Appoints Robert Huffines and Jacqueline Wright to Board of DirectorsFRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and
- BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening InitiativeFRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli
- BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care SegmentFRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.
- BD Names Gregory J. Hayes to Board of DirectorsFRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f
- Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsSAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
- Revelyst Announces Chief Supply Chain OfficerRevelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
- Zeus Names New Chief Executive OfficerZeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
- Zeus Names New Chief Executive OfficerZeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
- KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial OfficerKORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
- Azenta Announces CFO TransitionIndustry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
- BD Names Joanne Waldstreicher to Board of DirectorsFRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023. As chief medical officer, she provided visionary strategic and operational leadership at J&J, with global responsibility for safety, epidemiology, regulatory and clinical operations transformatio
- Michelle Quinn Named Acting General Counsel for BDFRANKLIN LAKES, N.J., Jan. 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently s
- LivaNova Board Appoints Brooke Story as a New DirectorLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022. In addition, Story will be a member of the Nominating and Corporate Governance Committee of the Board. Story joins the LivaNova Board with more than 20 years of experience in the global medical technology industry. She currently serves as Worldwide President, Integrated Diagnostic Solutions at BD (Becton, Dickinson and Company) a position she assumed in April 2021. Prior to that, she spent 15 years at Medtronic, where she held a variety of roles in finance, sales and business unit leader
- BD Promotes Two Senior Executives to Segment Leadership RolesMike Garrison Named EVP and President, Medical segmentRick Byrd Named EVP and President, Interventional segmentFRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive vice president (EVP) and president of the Medical segment, and Richard (Rick) Byrd has been named executive vice president (EVP) and president of the Interventional segment, both effective Sept. 6.
- Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of DirectorsNEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. "I could not be more pleased to welcome Drs. Strahlman and Palanki to our Board and look forward to their immediate contributions," stated Dr. Sean Ianchulev, chief executive officer and chief medical officer of Eyenovia. "Each brings decades of medical technology, cl
- BD Names William 'Bill' Brown to Board of DirectorsFRANKLIN LAKES, N.J., March 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022. Brown, 59, is currently the executive chair of L3Harris Technologies, a global aerospace and technology innovator with $18 billion in annual revenue and customers in more than 100 countries. Prior to this role, Brown served as chair and CEO of L3Harris from July 2019 to June 2021, after L3 and Harris merged in 2019. Prior to the
- BD Appoints Shana Neal as Chief People OfficerFRANKLIN LAKES, N.J., Feb. 23, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022. Neal, who held HR leadership positions at BD from 2005 to 2018, will oversee BD's Human Resources, Communications and Social Investing functions globally, including Talent Acquisition and Management; Total Rewards; HR Operations; HR Business Partnering; and Inclusion, Diversity, Equity and Engagement. She will report to BD's chairman, CEO
- Christopher Reidy Announces Intent to Retire from BDFRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Christopher Reidy, 64, executive vice president, chief financial officer (CFO) and chief administrative officer (CAO), has informed the company of his intent to retire as he reaches retirement eligibility. BD also announced that Reidy will become a director of the company formed in connection with the previously announced separation of the Diabetes Care business into an independent, publicly traded company ("NewCo")
- Elizabeth McCombs Appointed Chief Technology Officer at BDFRANKLIN LAKES, N.J., April 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021, succeeding John DeFord. McCombs, 45, will be responsible for continuing to drive the company's category innovation strategy and leading all research and development (R&D) activities, including executing the current innovation pipeline and developing the future product portfolio. "Beth has been an in
- T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical OfficerLEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new role, Dr. Ahuja will act as the company’s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems. “I am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics – especially for sepsis – are growing in importance as we continue to face mounting